The potential of nanomedicine therapies to treat neovascular disease in the retina

Journal of Angiogenesis Research

Volumn 2, Issue 1, 2010, Pages

  Farjo, Krysten M ^a   Ma, Jian Xing ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BEVASIRANIB; DENDRIMER; ENDOSTAR; ENDOSTATIN; FIBROBLAST GROWTH FACTOR INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE; GOLD NANOPARTICLE; LIPOSOME; PARVOVIRUS VECTOR; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; PLATELET DERIVED GROWTH FACTOR INHIBITOR; POLYMER; PROLACTIN; RANIBIZUMAB; RECOMBINANT K5 PROTEIN; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR A3K; SMALL INTERFERING RNA; TUMSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASOINHIBIN; VEGF TRAP EYE; VERTEPORFIN;

AMNESIA; ANTIANGIOGENIC ACTIVITY; CLINICAL TRIAL; DIABETIC RETINOPATHY; DISEASE COURSE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; LASER COAGULATION; LUNG NON SMALL CELL CANCER; MOTOR COORDINATION; NANOMEDICINE; NEUROTOXICITY; NONHUMAN; NONVIRAL GENE THERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE TUMOR; RETINA; RETINA DETACHMENT; RETINA ISCHEMIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; REVIEW; SEIZURE; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; VIRAL GENE THERAPY;

EID: 77957585612     PISSN: None     EISSN: 20402384     Source Type: Journal    
DOI: 10.1186/2040-2384-2-21     Document Type: Review

References (132)

1. Diabetic retinopathy. RN Frank, N Engl J Med 2004 350 48 58 10.1056/NEJMra021678 14702427
2. Diabetic eye disease. R Klein BE Klein, Lancet 1997 350 197 204 10.1016/S0140-6736(97)04195-0 9250197
3. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. EA Palmer JT Flynn RJ Hardy DL Phelps CL Phillips DB Schaffer B Tung, Ophthalmology 1991 98 1628 1640 1800923
4. Global data on visual impairment in the year 2002. S Resnikoff D Pascolini D Etya'ale I Kocur R Pararajasegaram GP Pokharel SP Mariotti, Bull World Health Organ 2004 82 844 851 15640920
5. The blood-ocular barriers. J Cunha-Vaz, Surv Ophthalmol 1979 23 279 296 10.1016/0039-6257(79)90158-9 380030
6. Blood-retinal barriers in health and disease. JG Cunha-Vaz, Trans Ophthalmol Soc U K 1980 100 337 340 6946626
7. Recent perspectives in ocular drug delivery. R Gaudana J Jwala SH Boddu AK Mitra, Pharm Res 2009 26 1197 1216 10.1007/s11095-008-9694-0 18758924
8. Drug delivery to the retina: challenges and opportunities. S Duvvuri S Majumdar AK Mitra, Expert Opin Biol Ther 2003 3 45 56 10.1517/14712598.3.1.45 12718730
9. Drug delivery for posterior segment eye disease. DH Geroski HF Edelhauser, Invest Ophthalmol Vis Sci 2000 41 961 964 10752928
10. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. DM Brown M Michels PK Kaiser JS Heier JP Sy T Ianchulev, Ophthalmology 2009 116 57 65 e55 10.1016/j.ophtha.2008.10.018 19118696
11. Emerging pharmacologic therapies for wet age-related macular degeneration. Z Ni P Hui, Ophthalmologica 2009 223 401 410 10.1159/000228926 19622904
12. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. P Sapieha JS Joyal JC Rivera E Kermorvant-Duchemin F Sennlaub P Hardy P Lachapelle S Chemtob, J Clin Invest 120 3022 3032 10.1172/JCI42142 20811158
13. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. J Ambati BK Ambati SH Yoo S Ianchulev AP Adamis, Surv Ophthalmol 2003 48 257 293 10.1016/S0039-6257(03)00030-4 12745003
14. Age-related macular degeneration (AMD): pathogenesis and therapy. JZ Nowak, Pharmacol Rep 2006 58 353 363 16845209
15. Vascular endothelial growth factor in eye disease. JS Penn A Madan RB Caldwell M Bartoli RW Caldwell ME Hartnett, Prog Retin Eye Res 2008 27 331 371 10.1016/j.preteyeres.2008.05.001 18653375
16. Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium - derived factor in brown norway and sprague dawley rats contributing to different susceptibilities to retinal neovascularization. G Gao Y Li J Fant CE Crosson SP Becerra JX Ma, Diabetes 2002 51 1218 1225 10.2337/diabetes.51.4.1218 11916948
17. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. G Gao Y Li D Zhang S Gee C Crosson J Ma, FEBS Lett 2001 489 270 276 10.1016/S0014-5793(01)02110-X 11165263
18. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. SX Zhang JJ Wang G Gao K Parke JX Ma, J Mol Endocrinol 2006 37 1 12 10.1677/jme.1.02008 16901919
19. Reduction of endogenous angiogenesis inhibitors in Bruch's membrane of the submacular region in eyes with age-related macular degeneration. IA Bhutto K Uno C Merges L Zhang DS McLeod GA Lutty, Arch Ophthalmol 2008 126 670 678 10.1001/archopht.126.5.670 18474778
20. Anti-VEGF therapy in proliferative diabetic retinopathy. W Abdallah AA Fawzi, Int Ophthalmol Clin 2009 49 95 107 10.1097/IIO.0b013e31819fd84a 19349790
21. Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. P Gehlbach AM Demetriades S Yamamoto T Deering EJ Duh HS Yang C Cingolani H Lai L Wei PA Campochiaro, Gene Ther 2003 10 637 646 10.1038/sj.gt.3301931 12692592
22. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? S Schaal HJ Kaplan TH Tezel, Ophthalmology 2008 115 2199 2205 10.1016/j.ophtha.2008.07.007 18930553
23. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. N Jo C Mailhos M Ju E Cheung J Bradley K Nishijima GS Robinson AP Adamis DT Shima, Am J Pathol 2006 168 2036 2053 10.2353/ajpath.2006.050588 16723717
24. Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. A Stahl L Paschek G Martin N Feltgen LL Hansen HT Agostini, Graefes Arch Clin Exp Ophthalmol 2009 247 767 773 10.1007/s00417-009-1058-x 19247683
25. Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. HC Hatcher JX Ma J Chao L Chao A Ottlecz, Invest Ophthalmol Vis Sci 1997 38 658 664 9071220
26. Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage. G Gao C Shao SX Zhang A Dudley J Fant JX Ma, Diabetologia 2003 46 689 698 12743698
27. Anti-inflammatory and antioxidant effects of SERPINA3K in the retina. B Zhang Y Hu JX Ma, Invest Ophthalmol Vis Sci 2009 50 3943 3952 10.1167/iovs.08-2954 19324842
28. Thrombospondin-1, PECAM-1, and regulation of angiogenesis. N Sheibani WA Frazier, Histol Histopathol 1999 14 285 294 9987673
29. Impaired expression of thrombospondin-1 in eyes with age related macular degeneration. K Uno IA Bhutto DS McLeod C Merges GA Lutty, Br J Ophthalmol 2006 90 48 54 10.1136/bjo.2005.074005 16361667
30. Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. S Wang Z Wu CM Sorenson J Lawler N Sheibani, Dev Dyn 2003 228 630 642 10.1002/dvdy.10412 14648840
31. Attenuation of retinal vascular development and neovascularization in transgenic mice over-expressing thrombospondin-1 in the lens. Z Wu S Wang CM Sorenson N Sheibani, Dev Dyn 2006 235 1908 1920 10.1002/dvdy.20837 16691615
32. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. SA Mousa W Lorelli PA Campochiaro, J Cell Biochem 1999 74 135 143 0.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-# 10381270
33. Attenuation of proliferation and migration of retinal pericytes in the absence of thrombospondin-1. EA Scheef CM Sorenson N Sheibani, Am J Physiol Cell Physiol 2009 296 724 734 10.1152/ajpcell.00409.2008 19193867
34. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. MS O'Reilly L Holmgren Y Shing C Chen RA Rosenthal M Moses WS Lane Y Cao EH Sage J Folkman, Cell 1994 79 315 328 10.1016/0092-8674(94)90200-3 7525077
35. Angiostatin inhibits pathological but not physiological retinal angiogenesis. TA Drixler IH Borel Rinkes ED Ritchie FW Treffers TJ van Vroonhoven MF Gebbink EE Voest, Invest Ophthalmol Vis Sci 2001 42 3325 3330 11726640
36. Recombinant adeno-associated virus vector expressing angiostatin inhibits preretinal neovascularization in adult rats. CC Lai WC Wu SL Chen MH Sun X Xiao L Ma KK Lin YP Tsao, Ophthalmic Res 2005 37 50 56 10.1159/000083040 15637422
37. Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. CC Lai WC Wu SL Chen X Xiao TC Tsai SJ Huan TL Chen RJ Tsai YP Tsao, Invest Ophthalmol Vis Sci 2001 42 2401 2407 11527956
38. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. Y Cao A Chen SS An RW Ji D Davidson M Llinas, J Biol Chem 1997 272 22924 22928 10.1074/jbc.272.36.22924 9278456
39. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. G Gao Y Li S Gee A Dudley J Fant C Crosson JX Ma, J Biol Chem 2002 277 9492 9497 10.1074/jbc.M108004200 11782462
40. Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. D Zhang PL Kaufman G Gao RA Saunders JX Ma, Diabetologia 2001 44 757 765 10.1007/s001250051685 11440369
41. Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes. SX Zhang J Sima C Shao J Fant Y Chen B Rohrer G Gao JX Ma, Diabetologia 2004 47 124 131 10.1007/s00125-003- 1276-4 14666366
42. Prolactins are natural inhibitors of angiogenesis in the retina. J Aranda JC Rivera MC Jeziorski J Riesgo-Escovar G Nava F Lopez-Barrera H Quiroz-Mercado P Berger G Martinez de la Escalera C Clapp, Invest Ophthalmol Vis Sci 2005 46 2947 2953 10.1167/iovs.05-0173 16043870
43. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. C Garcia J Aranda E Arnold S Thebault Y Macotela F Lopez-Casillas V Mendoza H Quiroz-Mercado HL Hernandez-Montiel SH Lin, et al. J Clin Invest 2008 118 2291 2300 18497878
44. Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. J Shen X Yang WH Xiao SF Hackett Y Sato PA Campochiaro, Faseb J 2006 20 723 725 16473886
45. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. MS O'Reilly T Boehm Y Shing N Fukai G Vasios WS Lane E Flynn JR Birkhead BR Olsen J Folkman, Cell 1997 88 277 285 10.1016/S0092-8674(00)81848-6 9008168
46. Collagen XVIII/endostatin is essential for vision and retinal pigment epithelial function. AG Marneros DR Keene U Hansen N Fukai K Moulton PL Goletz G Moiseyev BS Pawlyk W Halfter S Dong, et al. Embo J 2004 23 89 99 10.1038/sj.emboj.7600014 14685281
47. Endogenous endostatin inhibits choroidal neovascularization. AG Marneros H She H Zambarakji H Hashizume EJ Connolly I Kim ES Gragoudas JW Miller BR Olsen, Faseb J 2007 21 3809 3818 10.1096/fj.07-8422com 17526870
48. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. JP Eder Jr JG Supko JW Clark TA Puchalski R Garcia-Carbonero DP Ryan LN Shulman J Proper M Kirvan B Rattner, et al. J Clin Oncol 2002 20 3772 3784 10.1200/JCO.2002.02.082 12228197
49. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. MH Kulke EK Bergsland DP Ryan PC Enzinger TJ Lynch AX Zhu JA Meyerhardt JV Heymach WE Fogler C Sidor, et al. J Clin Oncol 2006 24 3555 3561 10.1200/JCO.2006.05.6762 16877721
50. [Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer]. L Yang JW Wang Y Sun YZ Zhu XQ Liu WL Li LJ Di PW Li YL Wang SP Song, et al. Zhonghua Zhong Liu Za Zhi 2006 28 138 141 16750022
51. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. Y Maeshima UL Yerramalla M Dhanabal KA Holthaus S Barbashov S Kharbanda C Reimer M Manfredi WM Dickerson R Kalluri, J Biol Chem 2001 276 31959 31968 10.1074/jbc.M103024200 11399763
52. Lasers and diabetic retinopathy: the art of gentle destruction. V Petrovic RB Bhisitkul, Diabetes Technol Ther 1999 1 177 187 10.1089/ 152091599317396 11475290
53. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. NM Bressler, Arch Ophthalmol 2001 119 198 207 11176980
54. Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. AF Cruess G Zlateva AM Pleil B Wirostko, Acta Ophthalmol 2009 87 118 132 10.1111/j.1755-3768.2008.01218.x 18577193
55. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. EW Ng DT Shima P Calias ET Cunningham Jr DR Guyer AP Adamis, Nat Rev Drug Discov 2006 5 123 132 10.1038/nrd1955 16518379
56. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. S Sacu S Michels F Prager G Weigert R Dunavoelgyi W Geitzenauer C Pruente U Schmidt-Erfurth, Eye (Lond) 2009 23 2223 2227 19169239
57. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Diabetic Retinopathy Clinical Research Network MJ Elman LP Aiello RW Beck NM Bressler SB Bressler AR Edwards FL Ferris SM Friedman AR Glassman KM Miller IU Scott CR Stockdale JK Sun, Ophthalmology 2010 117 1064 1077 e35 10.1016/j.ophtha.2010.02.031 20427088
58. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. QD Nguyen SM Shah DJ Browning H Hudson P Sonkin SM Hariprasad P Kaiser JS Slakter J Haller DV Do, et al. Ophthalmology 2009 116 2141 2148 e2141 10.1016/j.ophtha.2009.04.030 19700196
59. Complications of intravitreal injections. KM Sampat SJ Garg, Curr Opin Ophthalmol 2010 21 178 183 10.1097/ICU.0b013e328338679a 20375895
60. Protecting new ideas and inventions in nanomedicine with patents. R Bawa SR Bawa SB Maebius T Flynn C Wei, Nanomedicine 2005 1 150 158 17292072
61. Laser-Activated Gold-Nanoparticles as a Potential New Treatment Modality for Exudative Age-Related Macular Degeneration [abstract]. N Eter I Hahn F Levold E Endl, IOVS 2010 ARVO E-Abstract 2982
62. Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. JH Kim JH Kim KW Kim MH Kim YS Yu, Nanotechnology 2009 20 505101 10.1088/0957-4484/20/50/505101 19923650
63. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. SR Singh HE Grossniklaus SJ Kang HF Edelhauser BK Ambati UB Kompella, Gene Ther 2009 16 645 659 10.1038/gt.2008.185 19194480
64. Nanoparticles in medicine: therapeutic applications and developments. L Zhang FX Gu JM Chan AZ Wang RS Langer OC Farokhzad, Clin Pharmacol Ther 2008 83 761 769 10.1038/sj.clpt.6100400 17957183
65. Biological properties of "naked" metal nanoparticles. R Bhattacharya P Mukherjee, Adv Drug Deliv Rev 2008 60 1289 1306 10.1016/j.addr.2008.03.013 18501989
66. Gold nanoparticles in delivery applications. P Ghosh G Han M De CK Kim VM Rotello, Adv Drug Deliv Rev 2008 60 1307 1315 10.1016/j.addr.2008.03.016 18555555
67. Nanoparticulate systems for growth factor delivery. S Zhang H Uludag, Pharm Res 2009 26 1561 1580 10.1007/s11095-009-9897-z 19415467
68. Recent advances with liposomes as pharmaceutical carriers. VP Torchilin, Nat Rev Drug Discov 2005 4 145 160 10.1038/nrd1632 15688077
69. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Panyam MM Dali SK Sahoo W Ma SS Chakravarthi GL Amidon RJ Levy V Labhasetwar, J Control Release 2003 92 173 187 10.1016/S0168-3659(03)00328-6 14499195
70. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. J Panyam V Labhasetwar, Adv Drug Deliv Rev 2003 55 329 347 10.1016/S0169-409X(02)00228-4 12628320
71. Polymer conjugates as anticancer nanomedicines. R Duncan, Nat Rev Cancer 2006 6 688 701 10.1038/nrc1958 16900224
72. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. J Panyam WZ Zhou S Prabha SK Sahoo V Labhasetwar, Faseb J 2002 16 1217 1226 10.1096/fj.02-0088com 12153989
73. Dendrimers in gene delivery. C Dufes IF Uchegbu AG Schatzlein, Adv Drug Deliv Rev 2005 57 2177 2202 10.1016/j.addr.2005.09.017 16310284
74. Polysaccharides-based nanoparticles as drug delivery systems. Z Liu Y Jiao Y Wang C Zhou Z Zhang, Adv Drug Deliv Rev 2008 60 1650 1662 10.1016/j.addr.2008.09.001 18848591
75. Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties. MM Kemp A Kumar S Mousa E Dyskin M Yalcin P Ajayan RJ Linhardt SA Mousa, Nanotechnology 2009 20 455104 10.1088/0957-4484/20/45/ 455104 19822927
76. Synthesis of gold and silver nanoparticles stabilized with glycosaminoglycans having distinctive biological activities. MM Kemp A Kumar S Mousa TJ Park P Ajayan N Kubotera SA Mousa RJ Linhardt, Biomacromolecules 2009 10 589 595 10.1021/bm801266t 19226107
77. Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth. KT Al-Jamal WT Al-Jamal S Akerman JE Podesta A Yilmazer JA Turton A Bianco N Vargesson C Kanthou AT Florence, et al. Proc Natl Acad Sci USA 2010 107 3966 3971 10.1073/pnas.0908401107 20150514
78. Chitosan nanoparticles inhibit the growth of human hepatocellular carcinoma xenografts through an antiangiogenic mechanism. Y Xu Z Wen Z Xu, Anticancer Res 2009 29 5103 5109 20044623
79. Progress and problems with the use of viral vectors for gene therapy. CE Thomas A Ehrhardt MA Kay, Nat Rev Genet 2003 4 346 358 10.1038/nrg1066 12728277
80. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. F Simonelli AM Maguire F Testa EA Pierce F Mingozzi JL Bennicelli S Rossi K Marshall S Banfi EM Surace, et al. Mol Ther 2010 18 643 650 10.1038/mt.2009.277 19953081
81. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther 2002 13 3 13 10.1089/10430340152712629 11779411
82. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. S Hacein-Bey-Abina C von Kalle M Schmidt F Le Deist N Wulffraat E McIntyre I Radford JL Villeval CC Fraser M Cavazzana-Calvo A Fischer, N Engl J Med 2003 348 255 256 10.1056/NEJM200301163480314 12529469
83. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. SE Raper N Chirmule FS Lee NA Wivel A Bagg GP Gao JM Wilson ML Batshaw, Mol Genet Metab 2003 80 148 158 10.1016/j.ymgme.2003.08.016 14567964
84. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. AV Cideciyan WW Hauswirth TS Aleman S Kaushal SB Schwartz SL Boye EA Windsor TJ Conlon A Sumaroka JJ Pang, et al. Hum Gene Ther 2009 20 999 1004 10.1089/hum.2009.086 19583479
85. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. AM Maguire KA High A Auricchio JF Wright EA Pierce F Testa F Mingozzi JL Bennicelli GS Ying S Rossi, et al. Lancet 2009 374 1597 1605 10.1016/S0140-6736(09)61836-5 19854499
86. Subretinal delivery of recombinant AAV serotype 8 vector in dogs results in gene transfer to neurons in the brain. K Stieger MA Colle L Dubreil A Mendes-Madeira M Weber G Le Meur JY Deschamps N Provost D Nivard Y Cherel, et al. Mol Ther 2008 16 916 923 10.1038/mt.2008.41 18388922
87. Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. N Provost G Le Meur M Weber A Mendes-Madeira G Podevin Y Cherel MA Colle JY Deschamps P Moullier F Rolling, Mol Ther 2005 11 275 283 10.1016/j.ymthe.2004.09.022 15668139
88. Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. Y Saishin RL Silva Y Saishin S Kachi S Aslam YY Gong H Lai M Carrion B Harris M Hamilton, et al. Hum Gene Ther 2005 16 473 478 10.1089/hum.2005.16.473 15871678
89. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. PA Campochiaro QD Nguyen SM Shah ML Klein E Holz RN Frank DA Saperstein A Gupta JT Stout J Macko, et al. Hum Gene Ther 2006 17 167 176 10.1089/hum.2006.17.167 16454650
90. Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticles. TL Fink PJ Klepcyk SM Oette CR Gedeon SL Hyatt TH Kowalczyk RC Moen MJ Cooper, Gene Ther 2006 13 1048 1051 10.1038/sj.gt.3302761 16525478
91. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. R Farjo J Skaggs AB Quiambao MJ Cooper MI Naash, PLoS One 2006 1 38 10.1371/journal.pone.0000038 17183666
92. Nanoparticles of compacted DNA transfect postmitotic cells. G Liu D Li MK Pasumarthy TH Kowalczyk CR Gedeon SL Hyatt JM Payne TJ Miller P Brunovskis TL Fink, et al. J Biol Chem 2003 278 32578 32586 10.1074/jbc.M305776200 12807905
93. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. K Park Y Chen Y Hu AS Mayo UB Kompella R Longeras JX Ma, Diabetes 2009 58 1902 1913 10.2337/db08-1327 19491211
94. A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. E Gros S Deshayes MC Morris G Aldrian-Herrada J Depollier F Heitz G Divita, Biochim Biophys Acta 2006 1758 384 393 10.1016/j.bbamem.2006.02. 006 16545342
95. Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea. LN Johnson SM Cashman R Kumar-Singh, Mol Ther 2008 16 107 114 10.1038/sj.mt.6300324 17923842
96. A poly(ethylene) glycolylated peptide for ocular delivery compacts DNA into nanoparticles for gene delivery to post-mitotic tissues in vivo. S Parker Read SM Cashman R Kumar-Singh, J Gene Med 12 86 96 10.1002/jgm.1415 19937991
97. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. CC Berry, Nanomedicine (Lond) 2008 3 357 365 10.2217/17435889.3.3.357 18510430
98. Nuclear localization of HIV-1 tat functionalized gold nanoparticles. CC Berry JM de la Fuente M Mullin SW Chu AS Curtis, IEEE Trans Nanobioscience 2007 6 262 269 10.1109/TNB.2007.908973 18217618
99. Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. JM de la Fuente CC Berry, Bioconjug Chem 2005 16 1176 1180 10.1021/bc050033+ 16173795
100. The peptide carrier Pep-1 forms biologically efficient nanoparticle complexes. MA Munoz-Morris F Heitz G Divita MC Morris, Biochem Biophys Res Commun 2007 355 877 882 10.1016/j.bbrc.2007.02.046 17331466
101. Nanoparticles for retinal gene therapy. SM Conley MI Naash, Prog Retin Eye Res 2010 29 376 97 10.1016/j.preteyeres.2010.04.004 20452457
102. Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo. AG Ziady CR Gedeon T Miller W Quan JM Payne SL Hyatt TL Fink O Muhammad S Oette T Kowalczyk, et al. Mol Ther 2003 8 936 947 10.1016/j.ymthe.2003.07.007 14664796
103. Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA. X Chen DM Kube MJ Cooper PB Davis, Mol Ther 2008 16 333 342 10.1038/sj.mt.6300365 18059369
104. Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. X Cai SM Conley Z Nash SJ Fliesler MJ Cooper MI Naash, Faseb J 2010 24 1178 1191 10.1096/fj.09-139147 19952284
105. A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. X Cai Z Nash SM Conley SJ Fliesler MJ Cooper MI Naash, PLoS One 2009 4 5290 10.1371/journal.pone.0005290 19390689
106. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. MW Konstan PB Davis JS Wagener KA Hilliard RC Stern LJ Milgram TH Kowalczyk SL Hyatt TL Fink CR Gedeon, et al. Hum Gene Ther 2004 15 1255 1269 10.1089/hum.2004.15.1255 15684701
107. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. WM Stadler T Kuzel C Shapiro J Sosman J Clark NJ Vogelzang, J Clin Oncol 1999 17 2541 2545 10561320
108. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. P Bhargava JL Marshall N Rizvi W Dahut J Yoe M Figuera K Phipps VS Ong A Kato MJ Hawkins, Clin Cancer Res 1999 5 1989 1995 10473076
109. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. RS Herbst TL Madden HT Tran GR Blumenschein Jr CA Meyers LF Seabrooke FR Khuri VK Puduvalli V Allgood HA Fritsche Jr, et al. J Clin Oncol 2002 20 4440 4447 10.1200/JCO.2002.04.006 12431966
110. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. CJ Logothetis KK Wu LD Finn D Daliani W Figg H Ghaddar JU Gutterman, Clin Cancer Res 2001 7 1198 1203 11350884 (Pubitemid 32708670)
111. Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma. JD Moore BJ Dezube P Gill XJ Zhou EP Acosta JP Sommadossi, Cancer Chemother Pharmacol 2000 46 173 179 10.1007/s002800000149 11021733
112. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. HT Tran GR Blumenschein Jr C Lu CA Meyers V Papadimitrakopoulou FV Fossella R Zinner T Madden LG Smythe VK Puduvalli, et al. Cancer Chemother Pharmacol 2004 54 308 314 10.1007/s00280-004-0816-z 15184994
113. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. R Satchi-Fainaro M Puder JW Davies HT Tran DA Sampson AK Greene G Corfas J Folkman, Nat Med 2004 10 255 261 10.1038/nm1002 14981512
114. An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. O Benny O Fainaru A Adini F Cassiola L Bazinet I Adini E Pravda Y Nahmias S Koirala G Corfas, et al. Nat Biotechnol 2008 26 799 807 10.1038/nbt1415 18587385
115. Broad Spectrum Anitangiogenic Therapy for Ocular Neovascularization [abstract]. O Benny K Nakai T Yoshimura L Bazinet JD Akula RJ D'Amato, IOVS 2010 ARVO E-Abstract 2983
116. A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. H Li VV Tran Y Hu W Mark Saltzman CJ Barnstable J Tombran-Tink, Exp Eye Res 2006 83 824 833 10.1016/j.exer.2006.04.014 16822505
117. Integrins: the keys to unlocking angiogenesis. R Silva G D'Amico KM Hodivala-Dilke LE Reynolds, Arterioscler Thromb Vasc Biol 2008 28 1703 1713 10.1161/ATVBAHA.108.172015 18658045
118. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. W Cai Y Wu K Chen Q Cao DA Tice X Chen, Cancer Res 2006 66 9673 9681 10.1158/0008-5472.CAN-06- 1480 17018625
119. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. CN Landen TJ Kim YG Lin WM Merritt AA Kamat LY Han WA Spannuth AM Nick NB Jennnings MS Kinch, et al. Neoplasia 2008 10 1259 1267 18953435
120. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. DA Reardon KL Fink T Mikkelsen TF Cloughesy A O'Neill S Plotkin M Glantz P Ravin JJ Raizer KM Rich, et al. J Clin Oncol 2008 26 5610 5617 10.1200/JCO.2008.16. 7510 18981465
121. Targeting of ICAM-1-directed immunoliposomes specifically to activated endothelial cells with low cellular uptake: use of an optimized procedure for the coupling of low concentrations of antibody to liposomes. S Hua HI Chang NM Davies PJ Cabot, J Liposome Res 2010 20429814
122. PLGA nanoparticle - peptide conjugate effectively targets intercellular cell-adhesion molecule-1. N Zhang C Chittasupho C Duangrat TJ Siahaan C Berkland, Bioconjug Chem 2008 19 145 152 10.1021/bc700227z 17997512
123. Identification of a potent peptide antagonist to an active laminin-1 sequence that blocks angiogenesis and tumor growth. ML Ponce S Hibino AM Lebioda M Mochizuki M Nomizu HK Kleinman, Cancer Res 2003 63 5060 5064 12941835
124. Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats. H Kim KG Csaky, J Control Release 2010 142 286 293 10.1016/j.jconrel.2009.10.031 19895863
125. Nanotechnology - Guided Imaging and Therapy of Retinal Vascular Disease [abstract]. F Haselton PK Russ A Jayagopal, IOVS 2010 ARVO E-Abstract 424
126. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. CR Patra R Bhattacharya E Wang A Katarya JS Lau S Dutta M Muders S Wang SA Buhrow SL Safgren, et al. Cancer Res 2008 68 1970 1978 10.1158/0008-5472.CAN-07-6102 18339879
127. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. CR Patra R Bhattacharya D Mukhopadhyay P Mukherjee, Adv Drug Deliv Rev 62 346 361 10.1016/j.addr.2009.11.007 19914317
128. Targeted hyperthermia using metal nanoparticles. P Cherukuri ES Glazer SA Curley, Adv Drug Deliv Rev 62 339 345 10.1016/j.addr.2009.11.006 19909777
129. Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. N Singh S Amin E Richter S Rashid V Scoglietti PD Jani J Wang R Kaur J Ambati Z Dong BK Ambati, Invest Ophthalmol Vis Sci 2005 46 1647 1652 10.1167/iovs.04-1172 15851564
130. The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. I Chowers R Wong T Dentchev RH Farkas J Iacovelli TL Gunatilaka NE Medeiros JB Presley PA Campochiaro CA Curcio, et al. Invest Ophthalmol Vis Sci 2006 47 2135 2140 10.1167/iovs.05-1135 16639025
131. Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin. LN Johnson SM Cashman SP Read R Kumar-Singh, Vision Res 2010 50 686 697 10.1016/j.visres.2009.08.028 19733192
132. POD DNA Nanoparticles Rescue an Adult Mouse Model of Retinal Degeneration [abstract]. R Kumar-Singh SP Read SM Cashman, IOVS 2010 ARVO E-Abstract 3108